About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT00415636

Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

The purpose of this study is to evaluate the safety and tolerability of IC83/LY2603618 for the treatment of cancer.

Lead sponsor: Eli Lilly and Company•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Eli Lilly and Company

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Has at least one lesion that can be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST)
•Has fully recovered from all toxicities due to the following:
•1. Local radiation therapy that ended at least 14 days prior to Cycle 1, Day 1.
•2. Surgery.
•Has a life expectancy of at least 3 months.
•Negative serum pregnancy test.

Exclusion Criteria

•Is pregnant or breastfeeding.
•Is a woman of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards.
•Is a man of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards.
•Has a history of brain metastases, unless adequately treated and without radiologic evidence of progressive disease for at least 3 months after completion of therapy.
•Has a known active infection.

Related studies

Patient Anxiety During Magnetic Resonance Imaging

NCT07671846 · Cancer

RECRUITINGPhase 3

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

NCT06274047 · Androgen Axis Suppression, Prostatectomy, and more

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

NCT07209917 · Cervical Cancer, Human Papillomavirus (HPV) Infection, and more

Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates

NCT06689488 · Lung Cancer

RECRUITINGPhase 3

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671 · Locally Advanced Cervical Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 19, 2018Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment31

Start dateJan 2007

Last updatedOct 19, 2018

Condition

Locations shown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Scottsdale, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 19, 2018Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions